In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer ...

Researchers highlight how exercise and dietary strategies may complement immunotherapy by improving immune function, tumour ...

The tumor microenvironment (TME) is a metabolically dynamic niche where cancer cells and immune cells interact to influence tumor progression and immune ...

Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...

Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) were recently ...

Saudi Arabia approves Anktiva, an IL-15 immunotherapy, for bladder and lung cancer, marking its first regulatory clearance ...

A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...

Stanford University-led researchers report that tumor cells hijack mitochondria from immune cells, reducing anti-tumor immune ...

The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.

CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...

GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...